Immunome (IMNM) Interest Expenses (2019 - 2026)

Immunome's Interest Expenses history runs 8 years deep, the most recent figure standing at $184.9 million for Q1 2026.

• Quarterly Interest Expenses rose 69943.56% year-over-year to $184.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $184.9 million (up 27133.43% YoY) and the FY2025 annual result came in at $180.7 million, up 69.29% from the prior year.
• Interest Expenses was $184.9 million for Q1 2026 at Immunome, up from $243000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $184.9 million in Q1 2026 and bottomed at $16000.0 in Q4 2023.
• A 5-year average of $23.0 million and a median of $1.8 million in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses plunged 94.52% — and 2026, when it jumped 69943.56%.
• Immunome's Interest Expenses stood at $292000.0 in 2022, then plunged by 94.52% to $16000.0 in 2023, then jumped by 1768.75% to $299000.0 in 2024, then declined by 18.73% to $243000.0 in 2025, then soared by 75996.71% to $184.9 million in 2026.
• Business Quant data shows IMNM's Interest Expenses at $184.9 million in Q1 2026, $243000.0 in Q4 2025, and $41.8 million in Q3 2025.